Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor
Study Information
Alliance Study ID: N0272
NCT Study ID (ClinicalTrials.gov): NCT00049127
Alliance Committee: Neuro-Oncology
Disease or Cancer Type: Brain / Central Nervous System Cancer
Alliance Study Chair: Kurt Jaeckle, MD
Status: COMPLETED
Study Description
This phase I/II trial is studying the side effects and best dose of imatinib mesylate and to see how well it works in treating patients with a recurrent brain tumor that has not responded to previous surgery and radiation therapy. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information